Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc's SIVEXTRO (tedizolid phosphate) approved in U.S. to treat serious skin infections including those caused by MRSA


Friday, 20 Jun 2014 06:00pm EDT 

Cubist Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) approved SIVEXTRO (tedizolid phosphate) for treatment of adult acute bacterial skin and skin structure infections (ABSSSI).SIVEXTRO addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized by U.S. Centers for Disease Control and Prevention (CDC) as serious public health threat. 

Company Quote

75.65
0.69 +0.92%
26 Nov 2014